Display options
Cite
Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9(1):60doi: 10.1186/2049-6958-9-60.
Sanduzzi, A., Balbo, P., Candoli, P., Catapano, G. A., Contini, P., Mattei, A., Puglisi, G., Santoiemma, L., & Stanziola, A. A. (2014). COPD: adherence to therapy. Multidisciplinary respiratory medicine, 9(1), 60. https://doi.org/10.1186/2049-6958-9-60
Sanduzzi, Alessandro, et al. "COPD: adherence to therapy." Multidisciplinary respiratory medicine vol. 9,1 (2014): 60. doi: https://doi.org/10.1186/2049-6958-9-60
Sanduzzi A, Balbo P, Candoli P, Catapano GA, Contini P, Mattei A, Puglisi G, Santoiemma L, Stanziola AA. COPD: adherence to therapy. Multidiscip Respir Med. 2014 Nov 22;9(1):60. doi: 10.1186/2049-6958-9-60. eCollection 2014. PMID: 25485108; PMCID: PMC4256899.
Copy Download .nbib Format: NLM
Share it on

Multidiscip Respir Med. 2014 Nov 22;9(1):60. doi: 10.1186/2049-6958-9-60. eCollection 2014.

COPD: adherence to therapy.

Multidisciplinary respiratory medicine

Alessandro Sanduzzi, Piero Balbo, Piero Candoli, Giousuè A Catapano, Paola Contini, Alessio Mattei, Giovanni Puglisi, Luigi Santoiemma, Anna A Stanziola

Affiliations

  1. Department of Respiratory Diseases, Monaldi Hospital, University Federico II, Naples, Italy.
  2. Pneumology Thoracic Unit, Ospedale Maggiore della Carità, Novara, Italy.
  3. Pulmonary and Endoscopic Thoracic Unit, AUSL, Ravenna, Italy.
  4. Clinical Researcher, Respiratory Diseases, Institute of Clinical Physiology, G. Monasterio Tuscany Foundation/National Research Council, Pisa, Italy.
  5. Department of Respiratory Diseases, Bellaria Hospital, Bologna, Italy.
  6. Department of Pulmonary Diseases, Città della Salute e della Scienza Molinette, Torino, Italy.
  7. Department of Pulmonary Diseases, S. Camillo - Forlanini Hospital, Rome, Italy.
  8. Pharmacology Specialist, ASL, Bari, Italy.

PMID: 25485108 PMCID: PMC4256899 DOI: 10.1186/2049-6958-9-60

Abstract

Adherence to medical therapies is a growing issue, so much so that the World Health Organization defined it as "a new pharmacological problem". The main factors affecting compliance are: frequency of administration, rapid onset of action, role of device. The most severe consequence of non-adherence is the increased risk of poor clinical outcome, associated with worsening of the quality of life and increase in health-care expenditure. It appears crucial to identify those COPD patients who are "poorly or not at all compliant with their treatment". In order to evaluate adherence to the medical therapy, several methods were proposed, the most effective of which turned out to be self-reports, i.e. simple, brief questionnaires (e.g. Morisky test). To increase the likelihood of quickly identifying non-compliant patients, it may be useful to administer a simple questionnaire to naïve subjects (for example, in the waiting room before an examination) including six specific items allowing to identify the patient's key characteristics. Depending on the answers, patients who do not comply with their pharmacological treatment may be classified as belonging to 6 phenotypes. For patients who are already under treatment it might be useful to administer another short questionnaire during follow up examination. Once the risk of non-compliance is identified, four possible types of measures can be taken: prescription-related, educational, behavioral and complex combined measures (combination of two or more actions). Therefore, while it is clear that adherence in COPD is a critical issue, it is also obvious that raising awareness on the disease and improving cooperation among specialists, general practitioners, health-care professionals, and patients is the starting point at which this evolution should immediately begin. Each medication is able to foster good compliance with the therapy, and consequently to maximize the efficacy, by virtue of its specific inhaler and its own active ingredient.

Keywords: Adherence; COPD; Inhaler; LABA; LAMA; Questionnaire

References

  1. Eur Respir J. 1999 Nov;14(5):1034-7 - PubMed
  2. Cochrane Database Syst Rev. 2000;(2):CD000011 - PubMed
  3. Eur Respir J. 2002 Feb;19(2):246-51 - PubMed
  4. Int J Pharm. 2004 Sep 28;283(1-2):1-9 - PubMed
  5. N Engl J Med. 2005 Aug 4;353(5):487-97 - PubMed
  6. Respir Care. 2005 Oct;50(10):1304-12; discussion 1312 - PubMed
  7. Chest. 2005 Nov;128(5):3198-204 - PubMed
  8. Int J Clin Pract. 2005 Dec;59(12):1488-95 - PubMed
  9. N Engl J Med. 2007 Feb 22;356(8):775-89 - PubMed
  10. Respir Med. 2007 Dec;101(12):2511-9 - PubMed
  11. Respir Med. 2008 Jan;102(1):92-101 - PubMed
  12. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-9 - PubMed
  13. Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-84 - PubMed
  14. Respiration. 2009;78(3):322-8 - PubMed
  15. Respir Med. 2009 Dec;103(12):1832-7 - PubMed
  16. Thorax. 2010 Apr;65(4):298-302 - PubMed
  17. Patient Educ Couns. 2011 May;83(2):265-8 - PubMed
  18. Curr Med Res Opin. 2010 Oct;26(10):2421-9 - PubMed
  19. Curr Med Res Opin. 2010 Nov;26(11):2527-33 - PubMed
  20. Respir Med. 2011 Mar;105(3):435-41 - PubMed
  21. Int J Chron Obstruct Pulmon Dis. 2010 Nov 24;5:401-6 - PubMed
  22. BMC Pulm Med. 2011 Jan 24;11:6 - PubMed
  23. Respir Med. 2011 Jun;105(6):930-8 - PubMed
  24. Syst Rev. 2012 Dec 29;1:66 - PubMed
  25. Clin Med Res. 2013 Jun;11(2):54-65 - PubMed
  26. Int J Geriatr Psychiatry. 2014 Jan;29(1):49-57 - PubMed
  27. N Engl J Med. 2013 Aug 22;369(8):694-5 - PubMed
  28. Respir Res. 2013 Sep 22;14:94 - PubMed
  29. Int J Clin Pract. 2014 Oct;68(10):1200-8 - PubMed
  30. J Drug Assess. 2013 Feb 01;2(1):11-6 - PubMed
  31. Med Care. 1986 Jan;24(1):67-74 - PubMed
  32. Respir Med. 1998 Jan;92(1):105-10 - PubMed

Publication Types